Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

406 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.
Wagner-Johnston ND, Goy A, Rodriguez MA, Ehmann WC, Hamlin PA, Radford J, Thieblemont C, Suh C, Sweetenham J, Huang Y, Sullivan ST, Vandendries ER, Gisselbrecht C. Wagner-Johnston ND, et al. Among authors: thieblemont c. Leuk Lymphoma. 2015;56(10):2863-9. doi: 10.3109/10428194.2015.1017821. Epub 2015 Mar 29. Leuk Lymphoma. 2015. PMID: 25707288 Clinical Trial.
Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL).
Thieblemont C, Bouafia F, Hornez E, Dumontet C, Tartas S, Antal D, Lemieux B, Traullé C, Espinouse D, Salles G, Coiffier B. Thieblemont C, et al. Leuk Lymphoma. 2004 Apr;45(4):711-4. doi: 10.1080/10428190310001615675. Leuk Lymphoma. 2004. PMID: 15160944 Clinical Trial.
Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte.
Mounier N, Gisselbrecht C, Brière J, Haioun C, Feugier P, Offner F, Recher C, Stamatoullas A, Morschhauser F, Macro M, Thieblemont C, Sonet A, Fabiani B, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. Mounier N, et al. Among authors: thieblemont c. J Clin Oncol. 2004 Jul 15;22(14):2826-34. doi: 10.1200/JCO.2004.12.032. J Clin Oncol. 2004. PMID: 15254050
All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Mounier N, Gisselbrecht C, Brière J, Haioun C, Feugier P, Offner F, Recher C, Stamatoullas A, Morschhauser F, Macro M, Thieblemont C, Sonet A, Fabiani B, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. Mounier N, et al. Among authors: thieblemont c. Ann Oncol. 2004 Dec;15(12):1790-7. doi: 10.1093/annonc/mdh471. Ann Oncol. 2004. PMID: 15550584 Free article.
CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Bonnet C, Fillet G, Mounier N, Ganem G, Molina TJ, Thiéblemont C, Fermé C, Quesnel B, Martin C, Gisselbrecht C, Tilly H, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. Bonnet C, et al. Among authors: thieblemont c. J Clin Oncol. 2007 Mar 1;25(7):787-92. doi: 10.1200/JCO.2006.07.0722. Epub 2007 Jan 16. J Clin Oncol. 2007. PMID: 17228021 Free article. Clinical Trial.
Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria.
Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A, Felman P, Franco V, Iannitto E, Mollejo M, Papadaki T, Remstein ED, Salar A, Solé F, Stamatopoulos K, Thieblemont C, Traverse-Glehen A, Wotherspoon A, Coiffier B, Piris MA. Matutes E, et al. Among authors: thieblemont c. Leukemia. 2008 Mar;22(3):487-95. doi: 10.1038/sj.leu.2405068. Epub 2007 Dec 20. Leukemia. 2008. PMID: 18094718 Review.
Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study.
Jardin F, Jais JP, Molina TJ, Parmentier F, Picquenot JM, Ruminy P, Tilly H, Bastard C, Salles GA, Feugier P, Thieblemont C, Gisselbrecht C, de Reynies A, Coiffier B, Haioun C, Leroy K. Jardin F, et al. Among authors: thieblemont c. Blood. 2010 Aug 19;116(7):1092-104. doi: 10.1182/blood-2009-10-247122. Epub 2010 Apr 30. Blood. 2010. PMID: 20435884 Free article.
406 results